AdipoGen Life Sciences

AST-487

CHF 30.00
In stock
AG-CR1-3745-M0011 mgCHF 30.00
AG-CR1-3745-M0055 mgCHF 105.00
AG-CR1-3745-M02525 mgCHF 420.00
More Information
Product Details
Synonyms AST487; NVP-AST-487
Product Type Chemical
Properties
Formula

C26H30F3N7O2

MW 529.6
CAS 630124-46-8
Purity Chemicals ≥95%
Appearance White to off-white solid.
Solubility Soluble in DMSO, DMF or ethanol.
Identity Determined by 1H-NMR.
InChi Key ODPGGGTTYSGTGO-UHFFFAOYSA-N
Smiles CCN1CCN(CC2=C(C=C(NC(=O)NC3=CC=C(OC4=CC(NC)=NC=N4)C=C3)C=C2)C(F)(F)F)CC1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
Description
  • AST487 is an inhibitor of RET (IC50 = 0.88µM), FLT3 (Ki = 0.52µM), KDR (IC50 = 0.17µM), c-Abl (IC50 = 0.02µM) and c-Kit (IC50 = 0.5µM).
  • AST-487 has been shown to inhibit RET autophosphorylation and activation of downstream effectors and to prevent the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. In xenografts of NIH3T3 cells expressing oncogenic RET and of the MTC cell line TT in nude mice, AST-487 dose dependently inhibited tumor growth.
  • AST-487, which selectively targets mutant FLT3 protein kinase activity, is also shown to override PKC412 resistance in vitro, and has significant antileukemic activity in an in vivo model of FLT3-ITD(+) leukemia. The combination of AST-487 with standard chemotherapeutic agents leads to enhanced inhibition of proliferation of mutant FLT3-expressing cells. AST-487 displays high selectivity and potency toward FLT3 as a molecular target, and could potentially be used to override drug resistance in AML.
Product References
  1. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells: N. Akeno-Stuart, et al.; Cancer Res. 67, 6956 (2007)
  2. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells: E. Weisberg, et al.; Blood 112, 5161 (2008)
  3. Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison: E. Weisberg, et al.; Genes Cancer. 1, 1021 (2010)
  4. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells: M.L. Gild, et al.; Endocr. Relat. Cancer 20, 659 (2013)
  5. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts: E. Andreucci, et al.; Oncotarget 7, 80543 (2016)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.